Oncology providers' perspectives on endocrine therapy prescribing and management. - Wikidata - awgldk - TriplyDB

Oncology providers' perspectives on endocrine therapy prescribing and management.

Oncology providers' perspectives on endocrine therapy prescribing and management.

http://www.wikidata.org/entity/Q37316792

about

Barriers and facilitators of adjuvant hormone therapy adherence and persistence in women with breast cancer: a systematic review.Facilitating adherence to endocrine therapy in breast cancer: stability and predictive power of treatment expectations in a 2-year prospective study.

P2860

Q37669380-2336F07C-AFC7-48E0-894C-7CC8B9A01FF7 Q48250658-C093D109-FC11-4FB4-AF06-35ACE6615289

P2860

Oncology providers' perspectives on endocrine therapy prescribing and management.

http://www.wikidata.org/entity/Q37316792

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 30 September 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Oncology providers' perspectives on endocrine therapy prescribing and management.

@en

Oncology providers' perspectives on endocrine therapy prescribing and management.

@nl

type

label

Oncology providers' perspectives on endocrine therapy prescribing and management.

@en

Oncology providers' perspectives on endocrine therapy prescribing and management.

@nl

prefLabel

Oncology providers' perspectives on endocrine therapy prescribing and management.

@en

Oncology providers' perspectives on endocrine therapy prescribing and management.

@nl

P1433

Q37316792-BEDDFF02-CDE4-4B9A-99F3-B8FBE1DAB169

P1476

Q37316792-C2D588D7-9FB7-44EE-AA42-F2F77DD8021B

P2093

Q37316792-00C82819-DF57-49D0-878F-160F26DE1B45

Q37316792-627D5D2C-7658-4556-AE82-8AF1330F4B47

Q37316792-8106BB6F-DD8A-417A-8E59-4A15FA582DED

Q37316792-8624BE47-5303-4EE2-87CC-09D82A662446

Q37316792-8D7B9D7C-86DF-4BA2-9329-7F27A50EDDDB

Q37316792-A0DDC3D9-4094-4D5F-AB5F-485F32354074

Q37316792-DBD3CEC8-CDFB-4F7C-8A66-37753167263B

P2860

Q37316792-077CD07C-220B-4F97-89ED-8C797DE4BDD0

Q37316792-1473A46E-0173-41CA-A49C-95019226FE06

Q37316792-2AF45E1B-1F42-4579-8F96-64C3B77DFCBC

Q37316792-2E3404F8-D547-4792-9125-3B8BFC00C088

Q37316792-30C20F8B-97E7-4268-8FF5-C4F2FCF09D04

Q37316792-36EE5D6F-FE45-4850-B57C-659BA9CD8FAD

Q37316792-3DF179BA-F646-498D-B2B2-71451E337DCF

Q37316792-3F2B520D-3AC2-45A1-9D22-6424D4E6C611

Q37316792-44564A9A-52BD-46E3-9AA5-C7D436FB4FCD

Q37316792-5EDA2161-1CD2-4C43-8D5E-99C1509760C1

P304

Q37316792-B5F6F23F-42D0-4899-8FD2-D750B866D62B

P31

Q37316792-646B4CB8-A8C3-4CD9-8389-8B798B3A186F

P356

Q37316792-7155D226-61F5-4BB5-8C77-848E16C62C17

P407

Q37316792-37F7ECD2-1D2E-4597-9098-669507E76F17

P478

Q37316792-13264610-0E00-415A-904F-F0B043E8EB9B

P50

Q37316792-546E1140-C034-4283-BC5B-62ABF961C1CB

P577

Q37316792-BAC220CE-AD3D-4AEB-9D9D-8000E1ED28B0

P698

Q37316792-B3919724-8451-4AD9-A7FD-59135EB5F719

P932

Q37316792-CD7879E8-B405-43B8-8A60-F125B81DB4C2

P356

P1433

Patient Preference and Adherence

P1476

Oncology providers' perspectives on endocrine therapy prescribing and management.

@en

P2093

Carol E Golin

http://www.w3.org/2001/XMLSchema#string

Diane Bloom

http://www.w3.org/2001/XMLSchema#string

Jeffrey Peppercorn

http://www.w3.org/2001/XMLSchema#string

Jo Anne Earp

http://www.w3.org/2001/XMLSchema#string

Katherine E Reeder-Hayes

http://www.w3.org/2001/XMLSchema#string

Maya Espada

http://www.w3.org/2001/XMLSchema#string

Stephanie B Wheeler

http://www.w3.org/2001/XMLSchema#string

P2860

Racial/Ethnic and socioeconomic disparities in endocrine therapy adherence in breast cancer: a systematic review

Endocrine therapy use among elderly hormone receptor-positive breast cancer patients enrolled in Medicare Part D

National Cancer Institute Patient Navigation Research Program: methods, protocol, and measures.

A hard pill to swallow: a qualitative study of women's experiences of adjuvant endocrine therapy for breast cancer.

Managing aromatase inhibitors in breast cancer survivors: not just for oncologists

Can patient navigation improve receipt of recommended breast cancer care? Evidence from the National Patient Navigation Research Program

Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years.

Caring for survivors of breast cancer: perspective of the primary care physician

Adjuvant endocrine therapy in hormone receptor-positive postmenopausal breast cancer: evolution of NCCN, ASCO, and St Gallen recommendations.

Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial

P304

2007-2019

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/PPA.S95594

http://www.w3.org/2001/XMLSchema#string

P407

P478

10

http://www.w3.org/2001/XMLSchema#string

P50

Megan C Roberts

P577

2016-09-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27757021

http://www.w3.org/2001/XMLSchema#string

P932

5053382

http://www.w3.org/2001/XMLSchema#string